Cccc therapeutics pipeline
WebMar 31, 2024 · C4 Therapeutics Inc. (CCCC) full year performance was -87.60%. Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, C4 Therapeutics Inc. shares are logging -88.43% during the 52-week period from high price, and -6.06% … WebC4 Therapeutics, Inc. Financial Information: Market Cap: $693.09mil: Revenues: $0 mil (last 12 months) Net Income $-34.1 mil (last 12 months) IPO Profile: Symbol: CCCC: …
Cccc therapeutics pipeline
Did you know?
WebSep 29, 2024 · C4 Therapeutics has filed to raise $150 million in an IPO. The firm is developing protein degrading drugs for cancers and neurodegenerative diseases. … WebOur Science. Targeted protein degradation harnesses the cell’s innate capability to control protein levels to remove known drivers of disease.
WebJan 10, 2024 · C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein … WebMar 29, 2024 · C4 Therapeutics Inc is a bio-pharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecule medicines to …
WebMar 9, 2024 · Compare with up to 5 Stocks. On Wednesday 03/08/2024 the closing price of the C4 Therapeutics Inc Registered Shs share was $4.91 on NAS. Compared to the opening price on Wednesday 03/08/2024 on ... WebC4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...
WebApr 6, 2024 · The past year for C4 Therapeutics (NASDAQ:CCCC) investors has not been profitable finance.yahoo.com - November 13 at 4:37 PM: Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 227%: Read This Before Placing a Bet finance.yahoo.com - November 8 at 1:50 PM: SVB Securities Keeps Their Buy Rating on …
WebCCCC Stock 12 Months Forecast. $22.11. (627.30% Upside) Based on 9 Wall Street analysts offering 12 month price targets for C4 Therapeutics in the last 3 months. The average price target is $22.11 with a high forecast of $84.00 and a low forecast of $5.00. The average price target represents a 627.30% change from the last price of $3.04. tanner center birminghamWebFawn Creek Township is a locality in Kansas. Fawn Creek Township is situated nearby to the village Dearing and the hamlet Jefferson. Map. Directions. Satellite. Photo Map. tanner carlsonWebMar 23, 2024 · 88,6%. More Financials. Company. C4 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other … tanner ceiling lightWebWATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing … tanner chadwick go fund meWebC4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell ... tanner carson perfect gameWebDec 27, 2024 · C4 Therapeutics (NASDAQ:CCCC) - here’s another preclinical stage company that has a billion plus dollar valuation based on intellectual property and a few … tanner chadwickWebFind the latest C4 Therapeutics, Inc. (CCCC) stock quote, history, news and other vital information to help you with your stock trading and investing. tanner center for behavioral health